| 16.60 Delayed Data As of Aug 22 |  +0.09 / +0.55%Today’s Change | 15.50 Today|||52-Week Range 21.95 | -1.31% Year-to-Date |
| Is Takeda (TAK) a Profitable Stock for Value Investors Now? Aug 16 / Zacks.com - Paid Partner Content |
| Previous close | 16.51 |
| Today’s open | 16.60 |
| Day’s range | 16.59 - 16.75 |
| Volume | 699,624 |
| Average volume (3 months) | 1,858,012 |
| Market cap | $55.4B |
| Earnings growth (last year) | -52.61% |
| Earnings growth (this year) | -223.41% |
| Earnings growth (next 5 years) | +16.80% |
| Revenue growth (last year) | +18.39% |
| P/E ratio | 31.3 |
| Price/Sales | 2.08 |
| Price/Book | 1.19 |
| Today’s change | Today’s % change | |
|---|---|---|
| AGNAllergan | -0.32 | -0.20% |
| VRTXVertex Pharmaceutica... | -2.16 | -1.16% |
| ZTSZoetis Inc | -1.00 | -0.78% |
| CELGCelgene | +0.03 | +0.03% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $18.9B |
| Annual profit (last year) | $984.1M |
| Net profit margin | 5.20% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President, CEO & Representative Director Christophe Weber |
Chief Financial Officer Costa Saroukos |
Corporate headquarters Osaka, Osaka |
